X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1125) 1125
Book Review (410) 410
Publication (90) 90
Newsletter (19) 19
Book Chapter (13) 13
Dissertation (4) 4
Conference Proceeding (2) 2
Book / eBook (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (960) 960
humans (840) 840
thalidomide (646) 646
thalidomide - analogs & derivatives (383) 383
oncology (357) 357
male (355) 355
thalidomide - therapeutic use (338) 338
multiple myeloma (314) 314
female (310) 310
pharmacology & pharmacy (306) 306
animals (281) 281
multiple myeloma - drug therapy (279) 279
lenalidomide (271) 271
middle aged (234) 234
thalidomide - administration & dosage (223) 223
hematology (209) 209
aged (207) 207
thalidomide - adverse effects (201) 201
adult (198) 198
thalidomide - pharmacology (196) 196
thalidomide - pharmacokinetics (193) 193
bortezomib (183) 183
antineoplastic agents - therapeutic use (171) 171
pharmacokinetics (168) 168
cancer (156) 156
antineoplastic combined chemotherapy protocols - therapeutic use (155) 155
treatment outcome (149) 149
dexamethasone (145) 145
therapy (142) 142
medicine & public health (136) 136
care and treatment (133) 133
mice (117) 117
drug therapy (116) 116
multiple-myeloma (112) 112
research (109) 109
angiogenesis (105) 105
angiogenesis inhibitors - therapeutic use (102) 102
stem-cell transplantation (102) 102
chemotherapy (99) 99
clinical trials as topic (95) 95
dexamethasone - administration & dosage (95) 95
necrosis-factor-alpha (92) 92
dose-response relationship, drug (87) 87
aged, 80 and over (81) 81
analysis (77) 77
pharmacology/toxicology (77) 77
toxicology (77) 77
health aspects (76) 76
survival (76) 76
antineoplastic combined chemotherapy protocols - adverse effects (75) 75
pomalidomide (74) 74
antineoplastic agents - pharmacology (72) 72
tnf-alpha (72) 72
immunologic factors - therapeutic use (71) 71
thalidomide - chemistry (71) 71
clinical trials (69) 69
multiple myeloma - pathology (68) 68
antineoplastic agents - adverse effects (66) 66
combination (66) 66
in-vitro (63) 63
administration, oral (62) 62
angiogenesis inhibitors (61) 61
rats (59) 59
aids/hiv (57) 57
drugs (57) 57
hematology, oncology and palliative medicine (57) 57
neoplasms - drug therapy (57) 57
recurrence (57) 57
antineoplastic agents - administration & dosage (56) 56
dosage and administration (56) 56
efficacy (56) 56
expression (56) 56
phase-ii trial (56) 56
plus dexamethasone (56) 56
thalidomide - blood (56) 56
cells (55) 55
disease-free survival (53) 53
article (52) 52
thalidomide analogs (52) 52
immunosuppressive agents - therapeutic use (51) 51
myeloma (51) 51
cancer research (50) 50
immunology (50) 50
refractory multiple-myeloma (50) 50
metabolism (49) 49
antineoplastic combined chemotherapy protocols - administration & dosage (47) 47
low-dose dexamethasone (47) 47
stereoisomerism (47) 47
antineoplastic agents - pharmacokinetics (46) 46
immunomodulation (46) 46
apoptosis (45) 45
boronic acids - therapeutic use (45) 45
endothelial growth-factor (45) 45
internal medicine (45) 45
plasma (45) 45
pyrazines - therapeutic use (45) 45
safety (45) 45
cell line, tumor (44) 44
multiple myeloma - complications (44) 44
phase-ii (44) 44
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
New Zealand Veterinary Journal, ISSN 0048-0169, 07/2016, Volume 64, Issue 4, pp. 238 - 242
Journal Article
Journal Article
Blood, ISSN 0006-4971, 06/2017, Volume 129, Issue 25, pp. 3294 - 3303
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2016, Volume 78, Issue 1, pp. 173 - 182
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2018, Volume 182, Issue 2, pp. 231 - 244
Weekly ixazomib with lenalidomide‐dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma ( NDMM ) patients. This phase 1/2... 
newly diagnosed | multiple myeloma | oral | ixazomib | twice‐weekly | twice-weekly | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | PROTEASOME INHIBITOR IXAZOMIB | CYCLOPHOSPHAMIDE | AUTOLOGOUS TRANSPLANTATION | OPEN-LABEL | MAINTENANCE THERAPY | CARFILZOMIB | CONSOLIDATION THERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Boron Compounds - administration & dosage | Dose-Response Relationship, Drug | Multiple Myeloma - drug therapy | Aged, 80 and over | Lenalidomide - pharmacokinetics | Adult | Female | Glycine - administration & dosage | Glycine - pharmacokinetics | Dexamethasone - administration & dosage | Drug Administration Schedule | Administration, Oral | Boron Compounds - pharmacokinetics | Treatment Outcome | Dexamethasone - pharmacokinetics | Disease-Free Survival | Lenalidomide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lenalidomide - adverse effects | Boron Compounds - adverse effects | Aged | Complications and side effects | Medical research | Care and treatment | Hyperglycemia | Dexamethasone | Multiple myeloma | Medicine, Experimental | Steroids | Toxicity | Pharmacology | Pharmacokinetics | Peripheral neuropathy | Patients | Drug dosages | Index Medicus | Haematological Malignancy | Research Paper
Journal Article
The AAPS Journal, ISSN 1550-7416, 12/2012, Volume 14, Issue 4, pp. 872 - 882
Lenalidomide is a synthetic derivative of thalidomide exhibiting multiple immunomodulatory activities beneficial in the treatment of several hematological... 
Biochemistry, general | Biotechnology | mouse | Biomedicine | bioavailability | Pharmacy